Randomized trial shows significant weight loss in older adults using semaglutide — Evidence Review
Published by researchers at University of Padova, Novo Nordisk
Researched by
— the AI search engine for science
Table of Contents
A new analysis finds that semaglutide leads to significant weight loss and cardiometabolic improvements in older adults with obesity, with a safety profile generally consistent with prior research. Related studies broadly support these outcomes, confirming both the efficacy and common side effects of semaglutide and similar GLP-1 receptor agonists in diverse adult populations, including those without diabetes, as detailed by the University of Padova research group.
- The magnitude of weight loss and improvements in cardiometabolic risk factors observed in older adults closely mirror results from prior randomized controlled trials of semaglutide in broader adult populations, suggesting age does not substantially diminish the drug's effectiveness 6 8 10.
- Related studies confirm that semaglutide's most common side effects are gastrointestinal, with rare but notable risks such as dizziness or constipation; these safety trends are consistent across age groups, though some observational data highlight increased monitoring needs for older adults 6 8.
- Off-label use of semaglutide for weight loss is increasing, including among populations without type 2 diabetes, and studies indicate that rapid weight loss can have visible effects such as facial fat loss, which may present new clinical and ethical considerations 1 2 4 5.
Study Overview and Key Findings
Obesity is highly prevalent among older adults, who often present with multiple comorbidities and increased frailty, raising concerns about both the efficacy and safety of pharmacological weight-loss interventions in this group. The new analysis addresses a critical evidence gap by focusing specifically on adults aged 65 years and older, a population frequently underrepresented in clinical trials of obesity medications. Importantly, the study excludes individuals with diabetes to provide a clearer assessment of semaglutide's impact on weight loss and metabolic health in those with obesity or overweight, reflecting real-world use beyond diabetes management.
| Property | Value |
|---|---|
| Organization | University of Padova, Novo Nordisk |
| Authors | Prof Luca Busetto |
| Population | Older adults with obesity |
| Sample Size | n=358 |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Weight loss, waist circumference, cardiometabolic risk factors |
| Results | Semaglutide group lost −15.4% body weight vs −5.1% placebo |
Literature Review: Related Studies
To situate these findings in the broader research landscape, we searched the Consensus database, which indexes over 200 million research papers. The following search queries were used to identify relevant studies:
- Ozempic weight loss elderly adults
- semaglutide effects body weight reduction
- placebo comparison weight loss outcomes
Below, we summarize the key themes and findings emerging from related studies.
| Topic | Key Findings |
|---|---|
| What is the efficacy of semaglutide for weight loss in adults (including older adults)? | - Semaglutide consistently leads to substantial weight loss in adults with overweight or obesity, even without diabetes, with average losses between 14–16% in RCTs 6 8 10. - The proportion of patients achieving ≥10% or ≥15% weight loss is significantly higher with semaglutide compared to placebo, regardless of age 6 8 10. |
| How does semaglutide impact cardiometabolic risk factors and body composition? | - Semaglutide improves cardiometabolic parameters (blood pressure, cholesterol, blood glucose, waist circumference) beyond weight loss alone 6 8 10. - Improvements in physical functioning and reductions in obesity-related complications have also been observed 6 7 8. |
| What are the safety concerns and side effects associated with semaglutide and similar drugs? | - Gastrointestinal side effects (nausea, diarrhea, constipation) are common but usually mild to moderate; some users experience dizziness or rare hypoglycemia 6 8 10. - Rapid weight loss can produce visible facial changes ("Ozempic face"), which may require clinical attention 2 4. |
| What trends exist in the use and off-label prescribing of semaglutide? | - Off-label use of semaglutide for weight loss in non-diabetic adults has increased substantially, contributing to supply shortages 1. - Ethical debates have emerged regarding appropriate prescribing, especially for cosmetic purposes 5. |
What is the efficacy of semaglutide for weight loss in adults (including older adults)?
The current analysis aligns with previous randomized controlled trials showing that semaglutide yields robust weight loss in adults with overweight or obesity, with effect sizes in older adults comparable to those in younger populations. Both the STEP program and supporting studies report mean weight reductions of 14–16% over 68 weeks for semaglutide 2.4 mg, with over half of participants achieving double-digit percentage weight loss 6 8 10.
- The STEP 1, 3, 5, and 8 trials demonstrated mean weight losses of 14–16% with semaglutide in non-diabetic adults, closely matching figures observed in the new study's older cohort 6 8 10.
- Rates of clinically significant weight loss (≥10%, ≥15%) are consistently higher in semaglutide arms versus placebo, regardless of age 6 8.
- Comparative studies show that semaglutide outperforms other GLP-1 agonists, such as liraglutide, in both weight loss magnitude and achievement of major weight loss milestones 9.
- Observational data indicate increasing use of semaglutide outside its original diabetes indication, reflecting patient and clinician demand for effective obesity treatments even in older populations 1.
How does semaglutide impact cardiometabolic risk factors and body composition?
Semaglutide's benefits extend beyond weight reduction, as multiple studies confirm improvements in waist circumference, blood pressure, cholesterol, and blood sugar control. These findings, echoed in the current study, highlight semaglutide's potential to reduce the risk of obesity-related complications in older adults.
- Improvements in waist circumference and body mass index (BMI) categories are reproducible across STEP trials and the current study 6 8 10.
- Cardiometabolic risk markers—including blood pressure, cholesterol, and HbA1c—show significant improvement with semaglutide compared to placebo 6 8.
- Some trials report enhanced physical functioning and quality of life, which is particularly relevant for older adults with existing comorbidities 7.
- Long-term studies (up to 2 years) suggest these benefits are sustained over time 10.
What are the safety concerns and side effects associated with semaglutide and similar drugs?
The safety profile of semaglutide is well characterized: gastrointestinal side effects are the most common, but serious adverse events are rare and generally balanced against the benefits. The current study finds similar adverse event rates to prior research, with some signals—such as increased rates of constipation and dizziness—requiring monitoring in older adults.
- Gastrointestinal symptoms (nausea, diarrhea, constipation) are the predominant side effects, typically mild to moderate and self-limited 6 8 10.
- Discontinuation due to side effects is relatively low, though more common with semaglutide than placebo 6 8.
- Facial fat loss ("Ozempic face") and related cosmetic concerns have been increasingly recognized as a consequence of rapid weight loss, especially in older individuals 2 4.
- Serious adverse events remain infrequent, and rates of hypoglycemia and fractures are low, aligning with findings from meta-analyses of other GLP-1 agonists 6 12.
What trends exist in the use and off-label prescribing of semaglutide?
Semaglutide's popularity has grown rapidly, with off-label prescriptions for weight loss now common, including among those without diabetes or with milder obesity. This trend is raising ethical and supply concerns, particularly as media coverage and social media amplify issues like "Ozempic face."
- In Denmark and other countries, up to one-third of semaglutide prescriptions are now for patients without type 2 diabetes, reflecting off-label use for weight loss 1.
- Ethical debates center on appropriate indications for use, equity of access, and the balance of medical versus cosmetic motivations 5.
- Media-driven phenomena, such as concerns over facial changes, have spurred new guidelines for patient counseling and management in aesthetic medicine 2 4.
- Despite increased demand, most patients prescribed semaglutide for weight loss meet established medical criteria for pharmacologic intervention 1.
Future Research Questions
Although this study provides strong evidence for semaglutide's effectiveness and general safety in older adults, several important questions remain. Future research should address long-term outcomes, comparative effectiveness, and the broader impacts of widespread semaglutide use in aging populations.
| Research Question | Relevance |
|---|---|
| What are the long-term effects of semaglutide on frailty, muscle mass, and functional status in older adults? | Older adults are at risk for sarcopenia and functional decline; understanding whether semaglutide-induced weight loss impacts muscle or frailty is critical for patient safety and quality of life 6 10. |
| How do the cardiometabolic benefits of semaglutide differ between older and younger populations? | Comparative data are needed to determine if age modifies the drug’s impact on blood pressure, cholesterol, or glucose parameters 6 8. |
| What are the psychosocial and quality of life impacts of rapid weight loss and facial fat loss in older adults taking semaglutide? | The phenomenon of “Ozempic face” and related cosmetic changes may uniquely affect older adults, influencing self-image and mental health 2 4. |
| Is semaglutide cost-effective for weight management in older adults with multiple comorbidities? | Cost-effectiveness analyses are essential as healthcare systems weigh the benefits and potential risks of widespread semaglutide use in high-risk, older populations 1 5. |
| What strategies can optimize the safety and tolerability of semaglutide in older adults with obesity? | Further work is needed to identify risk factors and interventions that reduce adverse events, such as gastrointestinal symptoms or dizziness, in this medically vulnerable group 6 8. |